<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have shown previously that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>/testis (CT) antigen, CT45, is expressed in various epithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> at a frequency of &lt;5% to approximately 35% </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, the protein expression of CT45 was examined in non-Hodgkin B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by immunohistochemical analysis </plain></SENT>
<SENT sid="2" pm="."><plain>Serological response to CT45 was also evaluated by ELISA using CT45 recombinant protein and sera from patients with Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>None of the 80 low-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, expressed CT45 </plain></SENT>
<SENT sid="4" pm="."><plain>In comparison, CT45 was expressed in 28 of 126 (22%) diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>A remarkably high percentage (42/72, 58%) of classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> contained CT45-positive Reed-Sternberg cells </plain></SENT>
<SENT sid="6" pm="."><plain>Nodular <z:mp ids='MP_0000612'>sclerosis</z:mp> and mixed-cellularity subtypes had similar frequency of CT45 expression, but most EBV-positive cases were CT45 negative </plain></SENT>
<SENT sid="7" pm="."><plain>Gray-zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (cases with features of both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) also showed frequent (64%) CT45 expression </plain></SENT>
<SENT sid="8" pm="."><plain>Evaluation of reactive lymphoid tissues showed scattered CT45-positive lymphocytes in a single case of florid <z:hpo ids='HP_0002729'>follicular hyperplasia</z:hpo>, raising the possibility that this case was an evolving <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Despite frequent CT45 expression, only 1 of 67 Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients had detectable anti-CT45 antibodies in the serum, suggesting that the immune response to CT45 may be suppressed </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has the highest frequency of CT45 expression among <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> tested to date, the frequency of CT45 expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> is similar to that seen in epithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, and low-grade non-Hodgkin B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> do not express CT45 </plain></SENT>
</text></document>